Get startedLog in
    Picture of Actinium Pharmaceuticals logo

    ATNM — Actinium Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapSucker Stock
    All News

    Brief: Actinium Pharma reports 100% Remission Rate in Third Dose Cohort Of Actimab-A Clag-M Phase 1 Combination Trial

    Picture of Actinium Pharmaceuticals logoActinium Pharmaceuticals
    04/11/2020 18:48
    Nov 4 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM PHARMA - 100% REMISSION RATE REPORTED IN THIRD
DOSE
COHORT OF ACTIMAB-A CLAG-M PHASE 1 COMBINATION TRIAL

Source text for Eikon:  ID:nPn2hMBY9a 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Actinium Pharmaceuticals

    See all news